Han Zhu

Han Zhu

Auto-generated profile, based on publicly available information

Han Zhu

Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, People’s Republic of China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Hematology
Verified
Journal Article
Open access
XCXiao Chen
Xiao Chen
HZHan Zhu
Han Zhu
CQChun Qiao
Chun Qiao
SZSishu Zhao
Sishu Zhao
LLLu Liu
Lu Liu
YWYujie Wu
Yujie Wu
The study aims to understand geneome diversification and complexity that developed in Acute myeloid leukemia (AML).Next-generation sequencing (NGS) was used to identify the genetic profiles of 22 gen...

19 December 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
JHJiayu Huang
Jiayu Huang
HZHuihui Zhao
Huihui Zhao
MHMing Hong
Ming Hong
HZHan Zhu
Han Zhu
YZYu Zhu
Yu Zhu
SQsixuan qian
sixuan qian
Definite prognostic clinical factors of benefit for decitabine-based induction chemotherapy in elderly patients newly diagnosed with acute myeloid leukaemia (AML) are not identified. This study was designed to explore the potential biomarker, especially regeneration of haematopoiesis, of treatment response and survival in elderly patients with newly diagnosed AML. We analysed the clinical data of 117 elderly AML patients who were treated with a decitabine dose of 15 mg/m2 for 5 days, granulocyte colony-stimulating factor of 300 μg/d for priming, plus cytarabine 10 mg/m2 q12h for 7 days and aclarubicin 10 mg/d for 4 days (D-CAG). After initial induction chemotherapy, the overall response rate and complete remission (CR) were 71.8% and 58.1%, respectively. Patients responding to the D-CAG regimen achieved higher platelet counts on day 14 after initial treatment (p < 0.001). Median counts were 59.5 × 109/L in the CR group, 37 × 109/L in the partial remission group and 28 × 109/L in the non-responsive group. We then classified patients into those who achieved platelet counts≥60 × 109/L or 100 × 109/L on day 14 after D-CAG vs. those who did not. Platelet counts≥60 × 109/L or 100 × 109/L on day 14 were significantly associated with superior CR, overall survival and disease-free survival (80.9% vs. 45.3% p < 0.001,16.5 vs. 9.1 months p = 0.009 and 16.3 vs. 7.4 months p = 0.024; 85.2% vs. 50% p = 0.001, 31 vs. 10.1 months p = 0.003 and 16.9 vs. 8.9 months p = 0.006). Multivariate analysis confirmed that poor cytogenetics (p = 0.010) and FLT3-ITD mutation (p = 0.007) were identified as independent factors of OS, but not platelet count (p = 0.091). However, platelet count≥100 × 109/L on day 14 was an independent prognostic factor of CR and DFS. Platelet count recovery on day 14 after D-CAG induction chemotherapy is associated with response. D-CAG regimen was registered on ChicTR with number 11001700 .

1 January 2021 in Hematology
Verified
Journal Article
Open access
XSXing Shen
Xing Shen
JPJing Pan
Jing Pan
CQChenchen Qi
Chenchen Qi
YFYuan Feng
Yuan Feng
HWHanxin Wu
Hanxin Wu
HZHan Zhu
Han Zhu
To investigate the impact of minimal residual disease (MRD) before allogeneic hematopoietic stem cell transplantation (allo-HSCT) on the outcome of acute leukemia.Data from 114 patients who were di...

3 February 2022 in Leukemia Research
Verified
Journal Article
Closed access
HLHailing Liu
Hailing Liu
XSXiao Shi
Xiao Shi
LCLei Cao
Lei Cao
YMYi Miao
Yi Miao
XDXinyi Du
Xinyi Du
LFLei Fan
Lei Fan

7 June 2022 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
YLYanping Liu
Yanping Liu
ZDZiwen Duan
Ziwen Duan
FLFang Li
Fang Li
XZXiao Zhang
Xiao Zhang
RCRuize Chen
Ruize Chen
KMKourong Miao
Kourong Miao